Epicrispr Biotechnologies announced a $90 million Series C funding round.
- Amount
- $90M
- Stage
- Series C
- Announced
- 11 August 2026
- Investors
- Sanofi Ventures
- Use of funds
- Support pivotal clinical development of EPI-321, including preparing for registrational studies following the ongoing Phase I/II trial.
- Checked
- Amount and date checked against the press source